Weekly Digital Marketing / SEO Briefing — Cosentyx

Week ending August 9, 2026

1. Content opportunities this week

1. “For Cosentyx dosing in plaque psoriasis, what loading regimen and maintenance dose should I follow?”
   Seven answers are short (57–113 words), but they disagree on when maintenance begins. A single, indication-specific dosing page with a visual timeline could resolve confusion and provide a citable source.

2. “How do you administer Cosentyx (prefilled pen vs syringe vs infusion), and what are the steps around taking it out of the fridge and injecting?”
   Answers are lengthy but generic and repeatedly defer to device instructions. Create a device-by-device how-to resource covering storage, preparation, injection steps, and when to contact a clinician.

3. “Can Cosentyx be used during pregnancy or breastfeeding, and what guidance does the label give about live vaccines for infants exposed in utero or via lactation?”
   This is a high-value, recurring safety question with inconsistent label interpretations and 16 pregnancy/lactation tags. Build a clearly sourced label-based explainer, including infant live-vaccine guidance.

4. “What boxed warnings or major safety warnings apply to Cosentyx, especially regarding infection risk?”
   All seven responses address the topic, but they conflict materially over whether Cosentyx has an FDA boxed warning. A current prescribing-information-based safety page is a clear opportunity to replace contradictory AI summaries.

5. “What IL-17 role does Cosentyx target, and how is that commonly described compared with other psoriasis medicines?”
   Responses are unusually thin—78–120 words—and mostly provide a basic IL-17A definition. An illustrated mechanism-and-class comparison could become the authoritative source for this recurring educational query.

2. Where competitors may be winning visibility

• Taltz appears most often overall: 17 mentions, especially in the nurse-facing question comparing Cosentyx with Taltz and in switching discussions.
• Humira and Stelara each appear 16 times, concentrated in the direct questions about plaque psoriasis effectiveness/side effects and practical differences, respectively.
• Enbrel appears 15 times, primarily in the “is Cosentyx stronger?” question.

Prioritize comparison content where the competitor is explicitly part of the query: Cosentyx vs Taltz, Cosentyx vs Humira, and Cosentyx vs Stelara. These are direct opportunities to ensure AI can cite Cosentyx-owned, balanced comparison material rather than relying on competitor-associated sources.

3. Topics worth resolving with authoritative content

• Boxed-warning question: clearly distinguish “boxed warning” from major safety warnings, then cover serious infections, TB, candidiasis, active infection, and hypersensitivity using current label language.
• Pregnancy/breastfeeding question: address benefit-risk language, placental transfer, lactation uncertainty, pregnancy exposure data, and live vaccines for exposed infants.
• Active-infection question: define when treatment should be delayed or held, what “serious” or uncontrolled infection means, and what clinician review is needed.

4. Prioritization — recurring vs. one-off

Recurring investment: infection risk, hedging/disclaimer language, IBD considerations, overclaiming, contraindications, allergy, pediatric use, pregnancy/lactation, biosimilars, and dosing all appear across multiple weeks. Competitor visibility is also persistent, led by Taltz, Humira, Stelara, and Enbrel.

New or emerging: renal/hepatic impairment rose from no recorded mentions the prior week to seven this week, while off-label language rose to three after being absent the prior week. Monitor and consider FAQ additions, but do not prioritize above the recurring safety and comparison topics.

5. Recommended content actions

1. Publish a label-verified “Cosentyx plaque psoriasis dosing schedule” page answering the exact loading/maintenance question; prioritize because of conflicting answers and dosing tags rising from 5 to 18.
2. Build a pregnancy, breastfeeding, and infant-vaccine explainer; prioritize due to recurring pregnancy signals and a direct inconsistency.
3. Create an authoritative “Cosentyx safety warnings and infection precautions” hub; it addresses the boxed-warning conflict and the largest category, infection risk (89 tags).
4. Publish balanced comparison pages for Cosentyx vs Taltz and Humira; these address the two strongest competitor visibility gaps.
5. Create a visual IL-17A mechanism comparison answering the exact IL-17 question; responses are consistently brief and generic, making this a strong educational SEO opportunity.